Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2012 | Research

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

Authors: Angela M Sosin, Angelika M Burger, Aisha Siddiqi, Judith Abrams, Ramzi M Mohammad, Ayad M Al-Katib

Published in: Journal of Hematology & Oncology | Issue 1/2012

Abstract

Background

Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM2-p53 interaction by small-molecule inhibitors (SMIs). HDM2 have been developed and are under various stages of preclinical and clinical investigation. Previously, we examined the anti-lymphoma activity of MI-319, the laboratory grade of a new class of HDM2 SMI, the spiro-oxindole, in follicular lymphoma. Since then, MI-219, the clinical grade has become readily available. This study further examines the preclinical effects and mechanisms of MI-219 in a panel of human lymphoma cell lines as well as a cohort of patient-derived B-lymphcytes for its potential clinical use.

Results

Preclinical assessment of MI-219 was evaluated by means of an in vitro and ex vivo approach and compared to Nutlin-3, the gold standard. Characterization of p53 activity and stability were assessed by quantitative PCR, Western blot, and immunoprecipitation. Biological outcome was measured using Trypan blue exclusion assay, Annexin V/PI, PARP and caspase-3 cleavage. Surprisingly, the overall biological effects of Nutlin-3 were more delayed (48 h) while MI-219 triggered an earlier response (12-24 h), predominantly in the form of apoptotic cell death. Using a cell free autoubiquitination assay, neither agent interfered with HDM2 E3 ligase function. MI-219 was more effective in upregulating wt-p53 stabilization compared to Nutlin-3. MI-219, but not Nutlin-3, enhanced the autoubiquitination and degradation of HDM2.

Conclusions

Our data reveals unexpected differences between MI-219 and the well-studied Nutlin-3 in lymphoma cell lines and patient samples. We suggest a novel mechanism for MI-219 that alters the functional activity of HDM2 through enhanced autoubiquitination and degradation. Additionally, this mechanism appears to correspond to biological outcome. Our results provide evidence that different classes of HDM2 SMIs elicit molecular events that extend beyond HDM2-p53 dissociation which may be of biological and potentially therapeutic importance.

Available only for authorised users

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed

Collavin L, Lunardi A, Del Sal G: p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010, 17: 901-911. 10.1038/cdd.2010.35.CrossRefPubMed

Prives C, Hall PA: The p53 pathway. J Pathol. 1999, 187: 112-126. 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3.CrossRefPubMed

Oren M: Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999, 274: 36031-36034. 10.1074/jbc.274.51.36031.CrossRefPubMed

Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24: 2899-2908. 10.1038/sj.onc.1208615.CrossRefPubMed

Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991, 253: 49-53. 10.1126/science.1905840.CrossRefPubMed

Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD: Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 1997, 90: 4078-4091.PubMed

Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001, 61: 6185-6193.PubMed

10.

Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997, 75: 230-235. 10.1038/bjc.1997.38.PubMedCentralCrossRefPubMed

11.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M: Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003, 94: 394-399. 10.1111/j.1349-7006.2003.tb01453.x.CrossRefPubMed

12.

Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993, 362: 857-860. 10.1038/362857a0.CrossRefPubMed

13.

Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 1997, 387: 296-299. 10.1038/387296a0.CrossRefPubMed

14.

Momand J, Wu HH, Dasgupta G: MDM2–master regulator of the p53 tumor suppressor protein. Gene. 2000, 242: 15-29. 10.1016/S0378-1119(99)00487-4.CrossRefPubMed

15.

Iwakuma T, Lozano G: MDM2, an introduction. Mol Cancer Res. 2003, 1: 993-1000.PubMed

16.

Honda R, Yasuda H: Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000, 19: 1473-1476. 10.1038/sj.onc.1203464.CrossRefPubMed

17.

Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000, 275: 8945-8951. 10.1074/jbc.275.12.8945.CrossRefPubMed

18.

Stommel JM, Wahl GM: A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle. 2005, 4: 411-417. 10.4161/cc.4.3.1522.CrossRefPubMed

19.

Stommel JM, Wahl GM: Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004, 23: 1547-1556. 10.1038/sj.emboj.7600145.PubMedCentralCrossRefPubMed

20.

Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994, 84: 3158-3165.PubMed

21.

Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, Barbareschi M, Scarpa A, Mariuzzi GM, Pizzolo G: Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood. 1994, 84: 4295-4300.PubMed

22.

Zhang Wang H: MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000, 6: 393-416. 10.2174/1381612003400911.CrossRef

23.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007, 28: 622-629. 10.1002/humu.20495.CrossRefPubMed

24.

Mitani N, Niwa Y, Okamoto Y: Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007, 44: 557-559. 10.1258/000456307782268174.CrossRefPubMed

25.

Kojima K, Burks JK, Arts J, Andreeff M: The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010, 9: 2545-2557. 10.1158/1535-7163.MCT-10-0337.PubMedCentralCrossRefPubMed

26.

Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM: An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009, 8: 115-10.1186/1476-4598-8-115.PubMedCentralCrossRefPubMed

27.

Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7: 1126-1132. 10.1101/gad.7.7a.1126.CrossRefPubMed

28.

Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675.CrossRefPubMed

29.

Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003, 3: 102-109. 10.1038/nrc991.CrossRefPubMed

30.

Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer. 2002, 2: 594-604. 10.1038/nrc864.CrossRefPubMed

31.

Shangary S, Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009, 49: 223-241. 10.1146/annurev.pharmtox.48.113006.094723.PubMedCentralCrossRefPubMed

32.

Tabernero J, Dirix L, Schoffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z: A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011, 17: 6313-6321. 10.1158/1078-0432.CCR-11-1101.CrossRefPubMed

33.

Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008, 105: 3933-3938. 10.1073/pnas.0708917105.PubMedCentralCrossRefPubMed

34.

Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM: Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther. 2008, 7: 2445-2454. 10.1158/1535-7163.MCT-08-0063.PubMedCentralCrossRefPubMed

35.

Dias SS, Hogan C, Ochocka AM, Meek DW: Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett. 2009, 583: 3543-3548. 10.1016/j.febslet.2009.09.057.CrossRefPubMed

36.

Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ, Vousden KH: Phosphorylation of HDM2 by Akt. Oncogene. 2002, 21: 1955-1962. 10.1038/sj.onc.1205276.CrossRefPubMed

37.

Azmi AS, Beck FW, Sarkar FH, Mohammad RM: Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr Pharm Des. 2011, 17: 640-652. 10.2174/138161211795222612.CrossRefPubMed

38.

Moll UM, Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 2003, 1: 1001-1008.PubMed

39.

Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A: The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010, 17: 982-989. 10.1038/nsmb.1872.PubMedCentralCrossRefPubMed

40.

Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM: Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010, 10: 319-331. 10.2174/156800910791190229.PubMedCentralCrossRefPubMed

41.

Bixby D, Kujawski L, Wang S, Malek SN: The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle. 2008, 7: 971-979. 10.4161/cc.7.8.5754.CrossRefPubMed

42.

Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, Campas C, Barragan M, de Sevilla AF, Domingo A: MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006, 107: 4109-4114. 10.1182/blood-2005-08-3273.CrossRefPubMed

43.

Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT: Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005, 106: 3609-3617. 10.1182/blood-2005-04-1489.CrossRefPubMed

44.

Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M: MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005, 106: 3150-3159. 10.1182/blood-2005-02-0553.PubMedCentralCrossRefPubMed

45.

Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK, Pettitt AR: A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res. 2009, 69: 5210-5217. 10.1158/0008-5472.CAN-09-0627.CrossRefPubMed

46.

Pekova S, Cmejla R, Smolej L, Kozak T, Spacek M, Prucha M: Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leuk Res. 2008, 32: 395-400. 10.1016/j.leukres.2007.06.022.CrossRefPubMed

47.

Zauli G, di Iasio MG, Secchiero P: Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V: Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Curr Cancer Drug Targets. 2009, 9: 510-518. 10.2174/156800909788486777.CrossRefPubMed

48.

Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR, Lu H: Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 2006, 281: 24304-24313. 10.1074/jbc.M602596200.PubMedCentralCrossRefPubMed

49.

Lee MH, Lozano G: Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006, 16: 225-234. 10.1016/j.semcancer.2006.03.009.CrossRefPubMed

50.

Yan J, Zhang D, Di Y, Shi H, Rao H, Huo K: A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. FEBS Lett. 2010, 584: 3275-3278. 10.1016/j.febslet.2010.06.027.PubMedCentralCrossRefPubMed

51.

Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F, Meek D: FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett. 2009, 583: 621-626. 10.1016/j.febslet.2009.01.009.CrossRefPubMed

52.

Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY: ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 2011, 71: 6524-6534. 10.1158/0008-5472.CAN-11-0853.PubMedCentralCrossRefPubMed

53.

Zhao BX, Chen HZ, Lei NZ, Li GD, Zhao WX, Zhan YY, Liu B, Lin SC, Wu Q: p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J. 2006, 25: 5703-5715. 10.1038/sj.emboj.7601435.PubMedCentralCrossRefPubMed

54.

Song MS, Song SJ, Kim SY, Oh HJ, Lim DS: The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008, 27: 1863-1874. 10.1038/emboj.2008.115.PubMedCentralCrossRefPubMed

55.

Gopal YN, Chanchorn E, Van Dyke MW: Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther. 2009, 8: 552-562. 10.1158/1535-7163.MCT-08-0661.CrossRefPubMed

56.

Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010, 70: 9895-9904. 10.1158/0008-5472.CAN-10-1546.PubMedCentralCrossRefPubMed

57.

Mohammad RM, Mohamed AN, Smith MR: Jawadi NS, al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70: 62-67. 10.1016/0165-4608(93)90132-6.CrossRefPubMed

58.

Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM: Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 1998, 4: 1305-1314.PubMed

59.

Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006, 49: 3432-3435. 10.1021/jm051122a.CrossRefPubMed

60.

Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y: Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc. 2005, 127: 10130-10131. 10.1021/ja051147z.CrossRefPubMed

61.

Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, Erba H, Shedden K, Wang S, Malek SN: Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008, 111: 1584-1593.CrossRefPubMed

62.

Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77: 81-137.CrossRefPubMed

63.

Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed

Title: HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
Authors: Angela M Sosin
Angelika M Burger
Aisha Siddiqi
Judith Abrams
Ramzi M Mohammad
Ayad M Al-Katib
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-5-57

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

MicroRNAs in B cell development and malignancy

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

The significance of low PU.1 expression in patients with acute promyelocytic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer